← All trials
NCT06445023
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2024
- Primary completion
- Oct 31, 2026
- Completion date
- Apr 30, 2027
- First posted
- Jun 6, 2024
- Last posted
- Oct 17, 2024
- Enrollment
- 915
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Celldex TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.